Drug intelligence / Profile preview

chlorphenesin carbamate

Development stage
Phase 1
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

Chlorphenesin carbamate is a centrally acting skeletal muscle relaxant used for the symptomatic treatment of painful muscle spasm. It is a small molecule drug and the carbamate ester derivative of chlorphenesin. The drug acts primarily within the central nervous system (CNS), where it depresses spinal neuron activity, likely through slight hyperpolarization and/or prolongation of the refractory period in primary afferent terminals and motoneurons. This results in reduced transmission of nerve impulses involved in muscle contraction and pain sensation. Chlorphenesin carbamate also exhibits some antifungal and antibacterial properties but is mainly used for its muscle relaxant effects[1][6][7]. Its exact mechanism of action remains incompletely understood but does not involve direct action on skeletal muscles[6][7]. First approved in 1965, it has been marketed under several brand names including Maolate and Musil[4][7].

Brand names
MaolateMusilRinlaxer
Other names
3-(4-chlorophenoxy)-2-hydroxypropyl carbamate1,2-propanediol-3-(p-chlorophenoxy)-1-carbamate3-(4-chlorophenoxy)-1,2-propanediol-1-carbamatecarbamic acid 3-(p-chlorophenoxy)-2-hydroxypropyl ester

Beyond the preview

Go deeper on chlorphenesin carbamate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlorphenesin carbamate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call